Semmelweis University Department of Pediatrics (Bókay street Unit)
Budapest, Pest County, 1083, Hungary
Location status: Recruiting
NCT Number: NCT05836610
This is a prospective, single center, pharmacokinetic study of intravenous hydrocortisone therapy for systemic low blood pressure during hypothermia treatment in asphyxiated newborns. Patients will be allocated to hydrocortisone supplementation while receiving conventional inotropic therapy as needed.
The hypothesis is that a detailed study of hydrocortisone pharmacokinetics during therapeutic hypothermia would help to personalize steroid supplementation in asphyxiated neonates. As the overall metabolic rate decreases with lower body temperature, drug metabolism is likely to be reduced as well, and lower doses, or less frequent dosing will be sufficient to achieve the targeted steroid range and biological effects in asphyxiated neonates with relative adrenal insufficiency. Thus, the investigators are planning to measure initial, baseline serum cortisol levels and serial serum cortisol levels after hydrocortisone supplementation in cooled asphyxiated neonates.
Interested in participating?
Request InfoUp to 72 hour
All sexes
Interventional
Phase 4
Budapest, Pest County, 1083, Hungary
Location status: Recruiting
The ultimate goal of the present study, is to describe a new approach of more personalized and safe care to infants with birth asphyxia and hemodynamic instability.
Asphyxiated infants often present with multiorgan failure and low blood pressure. Therapeutic hypothermia, the standard of care, could worsen hemodynamic instability; therefore, treatment of cardiovascular impairment represents a major challenge in this clinical setting. An association was previously described between hypotension and low serum cortisol values in this patient population, and it was suggested that relative adrenal insufficiency (RAI) is an important factor in the circulatory compromise of these patients. In the "CORTISoL" clinical trial, it was also demonstrated that low-dose hydrocortisone therapy was effective in the treatment of cardiovascular impairment in asphyxiated neonates; however, some gaps remain in the knowledge on optimal dosing. Importantly, steroid therapy should be administered at the lowest effective dose and for the shortest possible duration in this vulnerable population.
In the current pharmacokinetic study, the investigators propose a stepwise approach to more detailed understanding of RAI and hydrocortisone pharmacokinetics in asphyxiated neonates. The findings would certainly aid clinical decision-making and allow for more personalized therapeutic interventions for the treatment of hemodynamic instability.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
intravenous bolus hydrocortisone therapy during hypothermia treatment
Other names: Solu-Cortef
Time frame: 2 hours
5 mmHg increase in mean arterial blood pressure after drug administration
Time frame: 72 hours
Length, cumulative and peak dose of inotrope treatment
Time frame: Before hydrocortisone administration within max. 72 hours
Low serum cortisol level at baseline
Time frame: 4-10 days
Brain injury on MRI examinations
Time frame: 18-42 month
Performance on motor and mental scales of Bayley III scales of infant development
Time frame: 72 hours
Presence of multiorgan failure during hypothermia
Contact information is provided by the study sponsor or research team.
Dobi Marianna, MD
CONTACT
Kata Kovacs, MD, PhD
CONTACT
Semmelweis University
Other
Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates - a Pharmacokinetic Study
Acronym: UniCort
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02700828
Asphyxia, Brain Diseases
Budapest, Pest County, Hungary
View Trial DetailsNCT05986994
Asphyxia, Asphyxia Perinatal
Naples, Italy
View Trial DetailsNCT00817401
Asphyxia, Body Temperature Changes
Zhengzhou, Henan, China
View Trial DetailsNCT00808704
Asphyxia, Brain Diseases
Zhengzhou, Henan, China
View Trial Details